Amgen Inc. Reports Q2 2026 Results, Provides Non‑GAAP Reconciliations

What Happened

• Amgen Inc. announced unaudited results for the three- and six-month periods ended June 30, 2026, in a press release dated August 4, 2026 (furnished as Exhibit 99.1 in the 8-K). The release includes both GAAP figures and a range of non‑GAAP financial measures and reconciliations. The company’s Chief Financial Officer, Peter H. Griffith, signed the filing on behalf of Amgen.

Key Details

• Periods covered: three and six months ended June 30, 2026; filing date: August 4, 2026.
• Non‑GAAP measures disclosed include non‑GAAP EPS, non‑GAAP operating income and margin, non‑GAAP tax rate, non‑GAAP operating expenses (and subcomponents: cost of sales, R&D, SG&A). Reconciliations to the most directly comparable GAAP measures are included.
• Free Cash Flow (FCF) is reported and defined as GAAP operating cash flow minus capital expenditures.
• Adjustments excluded from non‑GAAP measures are summarized: acquisition‑related charges (amortization/impairment of acquired intangibles and inventory step‑up), restructuring and cost‑savings charges, gains/losses on equity investments and certain legal items, with the tax impact of those adjustments disclosed.

Why It Matters

• The filing gives investors the company’s latest quarterly results and both GAAP and non‑GAAP perspectives—helpful for analyzing underlying operating performance and liquidity (via FCF).
• Amgen explains it uses these non‑GAAP measures internally for budgeting and performance assessments and provides reconciliations so investors can compare adjusted metrics to GAAP results.
• These non‑GAAP figures are supplemental (not a substitute for GAAP); investors should review the reconciliations and the specific excluded items to understand how adjusted metrics differ from reported GAAP results.